Prior to the extension, the Company was required to file the Annual Filings by
There have been no undisclosed material business developments since the filing of the last interim financial report. The Company acknowledges that management and other insiders are subject to a trading black-out policy that reflects the principles in Section 9 of National Policy 11-207 (Failure-to-File Cease
Contact:
Tel: 604.880.8822
Email: rogerf@calyxbio.com
This news release includes certain 'forward-looking statements' under applicable Canadian securities legislation. Forwardlooking statements include, but are not limited to, statements with respect to the anticipated timeline for filing of the Annual Filings and the Interim Filings. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
(C) 2020 Electronic News Publishing, source